3 IMvigor 210
First-line maintenance treatment: JAVELIN Bladder 100
5
Given the above success of immunotherapy in bladder cancer, there is great interest in the possibility of moving immunotherapy into the neoadjuvant disease space. Currently, there are many ongoing clinical trials for neoadjuvant immunotherapy:
6
7 and ABACUS
8 phase II trials. PURE-01 enrolled 143 patients that were treated with 3 cycles of pembrolizumab, resulting in a pT0 rate of 37%. ABACUS enrolled 95 patients that were treated with two cycles of atezolizumab, resulting in a pT0 rate of 31%. Three clinical trials have assessed the utility of immunotherapy combination therapy, including the NABUCCO (ipilimumab + nivolumab x 3), DUTRENEO (durvalumab + tremelimumab x 3), and durvalumab + tremelimumab x 2 (NCT02812420). As follows is a summary of these trials: